Full Press Release Details
EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer.
IMTX
EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
Key Takeaway: EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer